Histogen Inc. (HSTO) Stock

About Histogen Inc.

Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.

Histogen Inc. is headquartered in US.

Histogen Inc. (HSTO) stock trades at $0.02 with a market capitalization of $85435. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.01, reflecting a net loss over the last twelve months, price-to-book of 0.01, price-to-sales of 0.02. Over the past 52 weeks the stock has ranged between $0.02 and $0.02, and currently trades at or near its 52-week high.

On profitability, Histogen Inc. generates a return on equity (ROE) of -59.67% (negative, reflecting a net loss), return on capital employed of -59.66%, an operating margin of -282.38%, a net profit margin of -281.80%.

Official website: www.histogen.com